Mengyuan Li

Mengyuan Li

Auto-generated profile, based on publicly available information

Mengyuan Li

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
SRShengnan Ren
Shengnan Ren
ZZZhanyi Zhang
Zhanyi Zhang
MLMengyuan Li
Mengyuan Li
DWDAREN WANG
DAREN WANG
RGRuijie Guo
Ruijie Guo
FCFangfang Chen
Fangfang Chen
Cancer‑testis antigen (CTA) is a well‑accepted optimal target library for cancer diagnosis and treatment. Most CTAs are located on the X chromosome and aggregate into large gene families, such as the melanoma antigen, synovial sarcoma X and G antigen families. Members of the CTA subfamily are usually co‑expressed in tumor tissues and share similar structural characteristics and biological functions. As cancer vaccines are recommended to induce specific antitumor responses, CTAs, particularly CTA subfamilies, are widely used in the design of cancer vaccines. To date, DNA, mRNA and peptide vaccines have been commonly used to generate tumor‑specific CTAs in vivo and induce anticancer effects. Despite promising results in preclinical studies, the antitumor efficacy of CTA‑based vaccines is limited in clinical trials, which may be partially attributed to weak immunogenicity, low efficacy of antigen delivery and presentation processes, as well as a suppressive immune microenvironment. Recently, the development of nanomaterials has enhanced the cancer vaccination cascade, improved the antitumor performance and reduced off‑target effects. The present study provided an in‑depth review of the structural characteristics and biofunctions of the CTA subfamilies, summarised the design and utilisation of CTA‑based vaccine platforms and provided recommendations for developing nanomaterial‑derived CTA‑targeted vaccines.

7 October 2020 in Liver International
Verified
Journal Article
Open access
PDF file
MLMin Li
Min Li
LCLiu Chen
Liu Chen
YGYue Gao
Yue Gao
MLMengyuan Li
Mengyuan Li
Xiaosheng WangXiaosheng Wang
Xiaosheng Wang
XWXiaoping Wang
Xiaoping Wang
Liver plays a critical role in metabolism, nutrient storage and detoxification. Emergency signals or appropriate immune response leads to pathological inflammation and breaks the steady state when liver dysfunction appears, which makes body more susceptible to chronic liver infection, autoimmune diseases and tumour. Compelling proof has illustrated the non‐redundant importance of C‐C chemokine receptor type 2 (CCR2), one of G‐protein‐coupled receptors, in different diseases. Selectively expressed on the surface of cells, CCR2 is involved in various signalling pathways and regulates the migration of cells. Especially, a peculiar role of CCR2 has been identified within decades in the onset and progression of hepatic diseases, which led to particular focusing on CCR2 as a new therapeutic and diagnostic target for non‐alcoholic fatty liver disease and hepatocellular carcinoma. In this review, we discuss the effect of CCR2 in monocytes/macrophages on liver diseases. The application and translation of the decades of discoveries into therapies promise novel approaches in the treatment of liver disease.

15 July 2022 in Annals of Medicine
Verified
Journal Article
Open access
MLMengyuan Li
Mengyuan Li
DZDonghua Zhang
Donghua Zhang
DNA methylation is considered an essential epigenetic event during leukaemogenesis and the emergence of drug resistance, which is primarily regulated by DNA methyltransferases. DNA methyltransferase-1 (DNMT1) is one of the members of DNA methyltransferases, in charge of maintaining established methylation. Recently, DNMT1 is shown to promote malignant events of cancers through the epigenetic and non-epigenetic processes. Increasing studies in solid tumours have identified DNMT1 as a therapeutic target and a regulator of therapy resistance; however, it is unclear whether DNMT1 is a critical regulator in acute myeloid leukaemia (AML) and how it works. In this review, we summarized the recent understanding of DNMT1 in normal haematopoiesis and AML and discussed the possible functions of DNMT1 in promoting the development of AML and predicting the sensitivity of hypomethylation agents to better understand the relationship between DNMT1 and AML and to look for new hope to treat AML patients.

1 January 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
JGJingtian Guo
Jingtian Guo
YMYuxiao Ma
Yuxiao Ma
TTTiejun Tang
Tiejun Tang
ZBZhao-Lian Bian
Zhao-Lian Bian
QLQianwen Li
Qianwen Li
WGWei Guo
Wei Guo
Metastasis has been one of the most important causes of death from breast cancer, and chemotherapy remains the major option for metastatic breast cancer. However, drug resistance and higher toxicity from chemotherapy have been an obstacle for clinical practice, and the combination of chemotherapy with immunotherapy has emerged as a promising treatment strategy. Here, we describe a therapy based on the combination of disulfiram (DSF) and Cu2+ with widely used cytotoxic docetaxel (DTX). DSF/Cu-induced immunogenic cell death promoted the release of type I interferon and human monocyte-induced dendritic cell maturation, which established a foundation for the combination with chemotherapy. Consequently, the combination of DSF/Cu and DTX resulted in significantly more potent anti-tumor effects in 4T1-bearing mice than in single therapy. The present study has shed new light on combining DSF/Cu-induced immune responses with traditional chemotherapeutic agents to achieve greater benefits for patients with metastasis.

7 January 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
MLMengyuan Li
Mengyuan Li
XGXiaonan Guo
Xiaonan Guo
Xiaosheng WangXiaosheng Wang
Xiaosheng Wang
The coronavirus disease 2019 (COVID‐19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) began in December 2019 and was basically under control in April 2020 in Wuhan. To explore the impact of intervention measures on the COVID‐19 epidemic, we established susceptible–exposed–infectious–recovered (SEIR) models to predict the epidemic characteristics of COVID‐19 at four different phases (beginning, outbreak, recession, and plateau) from January 1st to March 30th, 2020. We found that the infection rate rapidly grew up to 0.3647 at Phase II from 0.1100 at Phase I and went down to 0.0600 and 0.0006 at Phase III and IV, respectively. The reproduction numbers of COVID‐19 were 10.7843, 13.8144, 1.4815, and 0.0137 at Phase I, II, III, and IV, respectively. These results suggest that intensive interventions, including compulsory home isolation and rapid improvement of medical resources, can effectively reduce the COVID‐19 transmission. Furthermore, the predicted COVID‐19 epidemic trend by our models was close to the actual epidemic trend in Wuhan. Our phase‐based SEIR models demonstrate that intensive intervention measures can effectively control COVID‐19 spread even without specific medicines and vaccines against this disease.

26 November 2025 in Future Integrative Medicine
Verified
Journal Article
Open access
XZXu Zhao
Xu Zhao
JCJingyi Chen
Jingyi Chen
HZHaowen Zhang
Haowen Zhang
MLMengyuan Li
Mengyuan Li